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Background: The sigma-2 receptor has been validated as a biomarker for proliferating tumours. Second mitochondria-derived
activator of caspase (Smac) is a protein released from mitochondria into the cytosol, leading to apoptosis. In this study,
we investigated a sigma-2 ligand as a tumour-targeting drug delivery agent for treating ovarian cancer.
Methods: A sigma-2 ligand, SW 43, was conjugated with a Smac mimetic compound (SMC), SW IV-52s, to form SW III-123. The
delivery function of the sigma-2 moiety and cell killing mechanisms of SW III-123 were examined in human ovarian cancer cell lines.
Results: SW III-123 internalisation into ovarian cancer cells was mediated by sigma-2 receptors. SW III-123, but not SW IV-52s or
SW 43, exhibited potent cytotoxicity in human ovarian cancer cell lines SKOV-3, CaOV-3 and BG-1 after 24-h treatment,
suggesting that the sigma-2 ligand successfully delivered SMC into ovarian cancer cells. SW III-123 induced rapid degradation of
inhibitor of apoptosis proteins (cIAP1 and cIAP2), accumulation of NF-kB-inducing kinase (NIK) and phosphorylation of NF-kB p65,
suggesting that SW III-123 activated both canonical and noncanonical NF-kB pathways in SKOV-3 cells. SW III-123 cleaved
caspase-8, -9 and -3. Tumour necrosis factor alpha (TNFa) antibody markedly blocked SW III-123-induced cell death and caspase-3
activity in SKOV-3 cells, indicating that SW III-123 activated both intrinsic and extrinsic apoptotic pathways and induced
TNFa-dependent cell death in SKOV-3 cells.
Conclusion: Sigma-2 ligands are a promising tumour-targeting drug delivery agent. Sigma-2-conjugated SMC exemplifies a novel
class of therapeutic drugs for treating ovarian cancer.
Ovarian cancer is the leading cause of death from gynaecological
malignancies, with approximately 21 550 new cases and 14 600
deaths occurring annually in the United States (Jemal et al, 2009).
Over the past two decades, the first-line chemotherapeutic drugs
for treating epithelial ovarian cancer have been the platinum-based
drug cisplatin and taxanes such as paclitaxel (Stordal et al, 2007;
Dinh et al, 2008). Most patients respond well initially to platinum
and taxane-based therapies, unfortunately resistance frequently
ensues. Moreover, the major limitation of conventional chemotherapy
is severe toxicity to normal tissues resulting from a lack of
selectivity towards cancer cells. Thus, cancer-selective targeting
has been recognised as an important goal in developing new
therapeutics (Torchilin, 2010).
In this study, we used a new strategy to deliver anticancer drugs
selectively into ovarian tumour cells by targeting sigma-2 receptors.
The sigma-2 receptor is overexpressed in various human tumours
(Bem et al, 1991; Vilner and Bowen, 1993; Vilner et al, 1995). Our
group has previously validated the sigma-2 receptor as a biomarker
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for imaging proliferating tumour cells (Mach et al, 1997; Wheeler
et al, 2000). The density of sigma-2 receptors in proliferative
tumour cells is approximately 10-fold higher than in nonproli-
ferative or quiescent tumour cells in cell culture and in solid
tumours. Sigma-2 receptor-selective radiotracers, developed in our
laboratory, have been shown to target various solid tumours in
rodents and in human patients using the functional imaging
technique, positron emission tomography (PET), and the uptake of
the sigma-2-selective radiotracer [18F]ISO-1 correlated with the
Ki-67 score in lymphoma, head and neck, and breast cancer
patients (Tu et al, 2005, 2007; Dehdashti et al, 2013). These data
demonstrate that sigma-2 receptor ligands possess high selectivity
for tumour cells vs normal tissues in vivo. In addition, we have
previously demonstrated that the fluorescent sigma-2 receptor
probe, SW 120, is rapidly internalised into cancer cells by an
endocytotic pathway and localises in multiple subcellular orga-
nelles such as mitochondria and endoplasmic reticulum (Zeng
et al, 2007, 2011), suggesting that sigma-2 receptor ligands are
excellent candidates to deliver anticancer drugs selectively into
tumours. This sigma-2 receptor-targeting strategy has shown the
initial success in pancreatic tumour xenograft mouse models
(Spitzer et al, 2012). Recently, our group has identified progester-
one receptor membrane component 1 as the potential sigma-2
receptor (Xu et al, 2011). This finding will facilitate further
investigations of sigma-2 receptor-selective ligands for imaging,
therapeutic and drug delivery applications.
Second mitochondria-derived activator of caspase (Smac) is a
protein released from mitochondria into the cytosol in response to
apoptotic stimuli (Du et al, 2000; Shiozaki and Shi, 2004). Smac
protein promotes apoptosis through binding to and antagonising
the activity of inhibitor of apoptosis proteins (IAPs) including
XIAP, cIAP-1 and cIAP-2, thus relieving them of their caspase-
binding partners and sensitising cells to apoptosis. XIAP binds and
inhibits caspase-9 through its baculovirus IAP repeat (BIR)
3 domain and caspase-3/7 through its BIR2 domain together with
the linker before BIR2. Smac interacts with the BIR2 or BIR3
domain of IAPs via the AVPI tetrapeptide-binding motif on the
N-terminus of Smac. Small-molecule Smac mimetic compounds
(SMC) have been developed by imitating the AVPI-binding motif
of Smac (Sun et al, 2008). SMC have been shown to sensitise
tumour cells to other anticancer drugs as well as to induce
apoptosis as single agents in a subset of tumour cells (Petersen
et al, 2007; Petrucci et al, 2007; Varfolomeev et al, 2007; Vince et al,
2007; Sun et al, 2008; Wang, 2011; Petrucci et al, 2012). SMC have
been introduced in phase I clinical trials (Gyrd-Hansen and Meier,
2010). However, a recent report indicated that SMC can increase
tumour metastasis in the bone via osteoclast activation (Yang et al,
2013). Therefore, it is important that SMC is delivered specifically
into tumour cells rather than normal tissues such as bone. In this
study, we aimed to use a sigma-2 ligand to deliver SMC into
ovarian cancer cells. We have conjugated a sigma-2 ligand, SW 43,
to a SMC, SW IV-52s, to form a sigma-2 receptor ligand-conjugated
SMC, SW III-123. We have shown that the sigma-2 ligand effectively
delivers SMC into ovarian cancer cells and potently induces cell
death. SW III-123 induced degradation of cIAP1 and cIAP2, NF-kB
activation, and tumour necrosis factor alpha (TNFa)-dependent
apoptosis in SKOV-3 cells, likely representing a novel class of
therapeutic drugs for treating ovarian cancer.
MATERIALS AND METHODS
Chemical synthesis of SW III-123 and SW IV-52s. 1H NMR
spectra were recorded on a Varian 300MHz NMR spectrometer
(Varian, Inc., Walnut Creek, CA, USA). Chemical shifts are reported
in d values (parts per million) relative to an internal standard of
tetramethylsilane. The following abbreviations are used for multiplicity
of NMR signals: br s¼ broad singlet, d¼ doublet, m¼multiplet,
s¼ singlet. Melting points were determined on an electrothermal
melting point apparatus and are uncorrected. Elemental analyses
were performed by Atlantic Microlab, Inc., Norcross, GA, USA and
were within±0.4% of the calculated values. Mass spectrometry was
provided by the Washington University Mass Spectrometry
Resource (Washington University, St Louis, MO, USA). All
reactions were carried out under an inert atmosphere of nitrogen.
General procedure for peptide coupling. 1-Ethyl-3-(3-dimethyla-
minopropyl)carbodiimide (EDCI; 1.1 eq) was added to a stirred
solution of the Boc-protected amino acid, N,N-diisopropylethyla-
mine (DIPEA; 1.1 eq) and 1-hydroxybenzotriazole (HOBt; 1.1 eq)
in DMF (15ml) at 0 1C. After 5min, the amino component (1.1 eq)
was added to the ice-cold solution, and the reaction mixture was
stirred overnight at room temperature. The mixture was diluted
with EtOAc and washed with 2% HCl solution, saturated NaHCO3
solution and brine, respectively. The organic layer was dried over
Na2SO4, and the volatiles were removed under reduced pressure.
The Boc-protected coupling product was purified by column
chromatography (silica gel, EtOAc: hexane¼ 1 : 2).
General procedure for removal of the Boc-protecting group. The
Boc-protected compound was stirred with trifluoroacetic acid in
dichloromethane (1 : 2) for 5 h at room temperature. The volatiles
were removed under reduced pressure, and the residue was basified
with saturated Na2CO3 solution, extracted with dichloromethane,
dried over Na2SO4, filtered and evaporated to give the product.
(S)-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)pyrrolidine-2-carbox-
amide (3). Using the general procedure for peptide coupling
and Boc removal, compound 3 was synthesised from Boc-proline
(Pro)-OH (1) and R-(-)-1,2,3,4-tetrahydro-1-napthylamine (2) as an
off-white powder (83% yield), mp 81–82 1C. 1H NMR (CDCl3)
d 7.90 (d, J¼ 8.8Hz, 1H), 7.09–7.17 (m, 4H), 5.10–5.16 (m, 1H),
3.28–3.87 (m, 1H), 2.97–3.02 (m, 1H), 2.73–2.90 (m, 4H), 1.98–2.21
(m, 3H), 1.70–1.87 (m, 5H).
(S)-1-((S)-2-amino-3,3-dimethylbutanoyl)-N-((R)-1,2,3,4-tetrahy-
dronaphthalen-1-yl) pyrrolidine-2-carboxamide (4). Using the
general procedure for peptide coupling and Boc removal,
compound 4 was synthesised from 3 and Boc-tert-leucine/
tert-butylglycine (Tle)-OH as an off-white solid (78% yield), mp
143–144 1C. 1H NMR (CDCl3) d 7.41 (d, J¼ 8.5Hz, 1H), 7.04–7.21
(m, 4H), 5.09–5.14 (m, 1H), 4.63–4.66 (m, 1H), 3.55–3.60 (m, 2H),
2.73–2.80 (m, 2H), 2.47–2.54 (m, 1H), 2.11–2.17 (m, 1H), 1.80–2.01
(m, 7H), 1.51 (br s, 2H), 0.80 (s, 9H).
(2S)-1-((2S)-2(2-chloropropanamido)-3,3-dimethylbutanoyl)-
N-((R)-1,2,3,4-tetrahydro-naphthalen-1-yl)pyrrolidine-2-carboxa-
mide (5). A mixture of compound 4, 2-chloropropionyl chloride
(1.2 eq) and triethylamine (3 eq) in dichloromethane (15ml) was
stirred at room temperature for 4 h, followed by adding saturated
aqueous NaHCO3 and stirred for 30min. The organic layer was
separated and evaporated. The resulting residue was purified by
column chromatography (5% methanol in dichloromethane) to
give 5 as a light yellow solid (81% yield), mp 158–159 1C. 1H NMR
(CDCl3) d 7.22–7.25 (m, 1H), 7.04–7.16 (m, 4H), 5.10–5.16
(m, 1H), 4.55–4.61 (m, 2H), 4.34–4.46 (m, 1H), 3.63–3.76 (m, 2H),
2.73–2.80 (m, 2H), 2.42–2.48 (m, 1H), 1.83–2.17 (m, 7H),




(2-methoxy-5-methylphenyl) carbamate (SW III-123). A mixture
of SW43 (350mg, 0.8mmol), 5 (340mg, 0.8mmol) and triethylamine
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(230mg, 2.3mmol) in THF (7ml) was heated at 65–70 1C for 6
days and evaporated. The resulting residue was purified by column
chromatography (8% methanol in dichloromethane) to give SW
III-123 as an off-white powder (137mg, 31% yield), mp 66-67 1C.
1H NMR (CDCl3) d 7.89–7.95 (m, 2H), 7.22–7.29 (m, 2H),
7.04–7.14 (m, 4H), 6.73–6.80 (m, 2H), 5.10–5.18 (m, 2H), 4.52–4.61
(m, 2H), 3.85 (s, 3H), 3.77–3.82 (m, 1H), 3.59–3.66 (m, 1H),
3.09–3.16 (m, 3H), 2.44–2.79 (m, 9H), 2.30 (s, 3H), 1.81–2.20
(m, 9H), 1.27–1.62 (m, 23H), 1.24 (d, J¼ 6.9Hz, 3H), 0.85 (s, 9H).
(S)-1-((S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)
butanoyl)-N-((R)-1,2,3,4-terahydronaphthalen-1-yl)pyrrolidine-
2-carboxamide oxalate (SW IV-52S). Using the general procedure
for peptide coupling from 4 and Boc-N-Me-alanine (Ala)-OH,
followed by Boc removal gave the product as a free amine
(55% yield). 1H NMR (CDCl3) d 7.74 (d, J¼ 9.8Hz, 1H), 7.22–7.24
(m, 2H), 7.04–7.14 (m, 3H), 5.12–5.14 (m, 1H), 4.58–4.61 (m, 1H),
4.55 (d, J¼ 9.8Hz, 1H), 3.79–3.84 (m, 1H), 3.64–3.67 (m, 1H),
3.05–3.07 (m, 1H), 2.73–2.79 (m, 2H), 2.43–2.47 (m, 1H), 2.34
(s, 3H), 2.10–2.18 (m, 1H), 1.95–2.01 (m, 2H), 1.82–1.89 (m, 4H),
1.56 (br s, 1H), 1.28 (d, J¼ 7.1Hz, 3H), 0.85 (s, 9H). The oxalate
salt was prepared using 1 equivalent of oxalic acid in ethanol to
give SW IV-52s as a light yellow solid, mp 148–149 1C. MS
m/z¼ 443 (MþH)þ . HRMS for [C25H39N4O3]þ 443.3022;
found: 443.3038. Anal. (C27H40N4O7, 0.5H2O): calculated, %: C
59.87; H 7.63; N 10.34; found, %: C 59.54, H 7.45, N 10.18.
Receptor-binding assays. The sigma-1 and sigma-2 receptor-
binding affinities of SW III-123 were determined as previously
described (Xu et al, 2005). Briefly, guinea pig brain (sigma-1 assay) or
rat liver (sigma-2 assay) membrane homogenates (B300mg protein)
were diluted with 50mM Tris-HCl, pH 8.0 and incubated with either
B5nM [3H](þ )-pentazocine (34.9Cimmol–1; sigma-1 assay) or 1nM
[3H]RHM-1 (80Cimmol–1; sigma-2 assay) in a total volume of 150ml
in 96-well plates at 25 1C. The concentrations of SW III-123 ranged
from 0.1nM to 10mM. After incubating for 60min, the reactions were
terminated by the addition of 150ml of cold wash buffer (10mM
Tris-HCl, 150mM NaCl, pH 7.4) using a 96-channel transfer pipette
(Fisher Scientific, Pittsburgh, PA, USA), and the samples harvested
and filtered rapidly into a 96-well fiberglass filter plate (Millipore,
Billerica, MA, USA) that had been presoaked with 100ml of 50mM
Tris-HCl, at pH 8.0 for 1h. Each filter was washed three times with
200ml of ice-cold wash buffer, and the bound radioactivity quantified
using a Wallac 1450 MicroBeta liquid scintillation counter (Perkin
Elmer, Boston, MA, USA). Nonspecific binding was determined in
the presence of 10mM cold haloperidol.
Cell culture conditions. The SKOV-3 human ovarian cancer cell
line was cultured in 5A McCoy’s medium containing 10% fetal
bovine serum (FBS), 2mM L-glutamine, and 100 unitsml–1 penicillin
and 100mgml–1 streptomycin. The CaOV-3 human ovarian cancer
cell line was cultured in DMEM containing 10% FBS, 2mM
L-glutamine, 100 unitsml–1 penicillin and 100mgml–1 streptomycin.
The BG-1 human ovarian cancer cell line was cultured in DMEM/F-12
containing 10% FBS, 2mM L-glutamine, 100unitsml–1 penicillin and
100 mgml–1 streptomycin. Cells were maintained in a humidified
incubator at 37 1C in a 5% CO2 atmosphere.
MTS cell proliferation assay. The cytotoxicity of the compounds
on SKOV-3, CaOV-3 and BG-1 human ovarian cancer cell lines
was measured by the MTS assay. The MTS assay was performed
using the CellTiter 96 Aqueous One Solution Assay (Promega,
Madison, WI, USA) which contains a tetrazolium compound
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt; MTS], according to the
manufacturer’s protocol. Briefly, cells were plated 4 103 cells per
well in 96-well plates 24 h before treatment with the compounds.
Each compound was dissolved in DMSO and serially diluted in
culture medium to acquire the desired concentrations. The final
concentration of DMSO in the cell culture medium was no more
than 1.0%. After a 24- or 48-h treatment with the various
compounds, 20 ml of the CellTiter 96 aqueous one solution reagent
was added to each well, and the plate was incubated for 1–2 h at
37 1C. The plate was then read at 490 nm in a Victor3 plate reader
(PerkinElmer Life and Analytical Sciences, Shelton, CT, USA). The
EC50, defined as the concentration of the sigma ligand required to
inhibit cell proliferation by 50% relative to untreated cells, was
determined from the dose-response curves generated using GraFit
software, version 5 (Erithacus Software Limited, West Sussex, UK).
All the compounds were assayed in triplicate, and the EC50 values
presented as the mean±s.e.m. of three independent experiments.
Caspase-3 cell assay. The caspase-3 activity induced by the
compounds in SKOV-3 cells was measured using the Apo-ONE
Homogeneous Caspase-3/7 Assay (Promega). This assay utilises a
profluorescent substrate Z-DEVD-R110 specific for caspase-3/7
coupled with an optimised cell permeabilisation buffer. Cleavage of
the peptide sequence DEVD by active caspase-3/7 releases free
Rhodamine 110, which when excited at 485 nm, becomes intensely
fluorescent and can be detected at emission wavelength 535 nm.
The amount of fluorescent product generated is directly propor-
tional to the caspase-3/7 activity in each sample. SKOV-3 cells
were plated 4 103 cells per well in 96-well black, clear-bottomed
plates 24 h before treatment with the compounds. After a 24-h
treatment with the various compounds, caspase-3 activity was
assessed using the Apo-ONE Homogeneous Caspase-3/7 Assay.
In all, 10ml of buffer was pre-mixed with 100 ml of the caspase-3/7
substrate Z-DEVD-R110. In total, 100 ml of the substrate-buffer
mix was added to each well and the plate was placed on an orbital
shaker for 5min. The plate was then incubated at room
temperature in the dark for up to 18 h. The plate was then read
at excitation and emission wavelengths 485 and 535 nm,
respectively, on a Victor3 plate reader (PerkinElmer Life and
Analytical Sciences). Caspase-3 activation was determined by
comparing maximal response values with untreated controls and
results were plotted as increase over baseline.
Blocking studies of internalisation of SW 120 in SKOV-3
cells. SKOV-3 cells were plated in 100mm dishes at 5 105 cells
per dish for 24 h before treatment with compounds. The cells were
incubated with 0, 0.3, 1, 3 and 10mM SW 43, SW IV-52s or SW III-
123 for 30min at 37 1C. In all, 10 nM SW 120 was then added to
the cell culture dishes containing the above blocking compounds.
After 30-min incubation at 37 1C, the cells were washed with
phosphate-buffered saline (PBS) twice and detached with 0.05%
trypsin-EDTA (Life Technologies, Grand Island, NY, USA). The
cells were centrifuged at 1000 g for 5min. The cell pellets were
washed with PBS twice. Internalisation of SW 120 into the cells
was analysed by flow cytometer. Flow Cytometric analysis was
performed using a FACScan DxP10 (BD Bioscience, San Jose, CA,
USA, and Cytek Development, Fremont, CA, USA), equipped with
a 30mW Coherent Sapphire solid state 488 nm laser to excite SW
120. Emission was captured with a 530/30 bandpass filter.
Western blot analysis. SKOV-3 cells (1 106 per dish) were
plated in 100mm culture dishes 24 h before drug treatment. For
dose-response experiments, cells were treated with 0, 1, 3 or 10mM
SW 43, SW IV-52s or SW III-123 for 24 h. For time course
experiments, cells were treated with 3mM SW 43, SW IV-52s or
SW III-123 for 0, 0.5, 2, 6 or 24 h. The cells were then harvested
and lysed in radioimmunoprecipitation assay buffer (50mM Tris,
150mM sodium chloride, 1.0mM EDTA, 1% Nonidet P40, and
0.25% SDS (pH 7.0)), supplemented with complete protease
inhibitor cocktail (Roche, Mannheim, Germany) and phosphatase
inhibitor cocktail 1 (Sigma Chemical Co., St Louis, MO, USA). The
cells were sonicated briefly, centrifuged at 13 000 g for 20min at
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4 1C, and the supernatant collected. The protein concentration was
determined using a Bio-Rad Dc protein assay kit (Bio-Rad
Laboratories, Hercules, CA, USA). Lysates containing 30 mg of
protein were run on a 12% acrylamide gel and transferred to a
PVDF membrane (Bio-Rad Laboratories). The PVDF membrane
was incubated with 5% nonfat dry milk for 1 h at room
temperature, then overnight with a primary antibody at 4 1C,
and finally with the secondary antibody, horseradish peroxidase
(HRP)-conjugated IgG. The SuperSignal West Pico Chemilumi-
nescent Substrate assay kit (Pierce Biotechnology, Inc., Rockford,
IL, USA) was used to detect the secondary antibody. For stripping
western blots, the blot was incubated with stripping buffer (Pierce
Biotechnology Inc.) for 15min at room temperature.
Rabbit antibodies of caspase-3, caspase-9, XIAP, NIK, NF-kB
p65, phospho-NF-kB p65 (Ser536), actin and mouse antibody of
caspase-8 were purchased from Cell Signaling Technology
(Danvers, MA, USA). The goat antibody of cIAP1 and the mouse
antibody of cIAP2 were from R&D Systems (Minneapolis, MN,
USA). All the primary antibodies were used at a dilution
recommended by the manufacturer. The secondary antibody was
HRP-conjugated goat anti-rabbit IgG, HRP-conjugated horse anti-
mouse IgG (Cell Signaling Technology) or HRP-conjugated rabbit
anti-goat IgG (R&D Systems) at a 1 : 3000, 1 : 10000 or 1 : 1000
dilution, respectively.
Statistical analysis. The results are expressed as the mean±s.e.m.
based on three independent experiments performed in triplicate.
Differences among groups were statistically analysed using a two-
tailed Student’s t-test. A P-value of o0.05 was considered
significant.
RESULTS
Synthesis of SW IV-52s and SW III-123. The syntheses of SW
III-123 and SW IV-52s (Oost et al, 2004; Sun et al, 2008) were
outlined in Figure 1. Condensation of commercially available
Boc-Pro-OH (1) and R-(-)-1,2,3,4-tetrahydro-1-nathylamine (2) in
the presence of EDCI, DIPEA and HOBt, followed by removal of
the Boc-protecting group gave 3. Condensation of 3 with
Boc-Tle-OH, followed by removal of the Boc-protecting group
gave 4. Alkylation of 4 with 2-chloropropionyl chloride gave 5.
Reaction of 5 with amine SW 43 (Vangveravong et al, 2006)
gave the desired product SW III-123 in 16% yield (overall).
Condensation of 4 with Boc-N-Me-Ala-OH and removal of the
Boc-protecting group gave SW IV-52s in 36% yield (overall).
SW III-123 has adequate sigma-2 receptor-binding affinity
(Ki,s2 ¼ 189.90±12.84 nM), whereas it has low sigma-1
receptor-binding affinity (Ki,s1¼ 2046.30±62.62 nM).
SW III-123 potently induced cell death in ovarian cancer
cells. SKOV-3 cells were treated with increasing doses of SW 43,






























































































Reagents: (a) EDCI, DIPEA, HOBt, DMF; (b) TFA, CH2Cl2: (c) Boc-Tle-OH, EDCI, DIPEA, HOBt,
DMF; (d) 2-chloropropionyl chloride, (CH3CH2)3N, CH2Cl2; (e) SW43, K2CO3, KI, CH3CN, heat
Reagents: (a) Boc-N-Me-Ala-OH, EDCI, DIPEA, HOBt, DMF; (b) TFA, CH2Cl2; (c) oxalic acid, EtOH.
Figure 1. The synthetic schemes for generating SW III-123 (A) and SW IV-52s (B).
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for 24 h, MTS assay were performed to measure the cytotoxicity of
these compounds. The results showed that SW III-123-induced
cell death potently (EC50¼ 4.0 mM) after 24-h treatment, whereas
SW 43, SW IV-52s, or a combination of SW 43 and SW IV-52s
significantly shifted the dose-response curve rightward (Figure 2A).
SW 43 showed cytotoxic effects but at higher doses than
SW III-123. SW IV-52s showed minor cytotoxicity after 24-h
treatment (EC50 4100 mM), but exhibited potent cytotoxicity after
48-h treatment (EC50¼ 0.7mM) in SKOV-3 cells (Table 1 and
Supplementary Figure 1). The results suggest that SW IV-52s does
not penetrate cells efficiently during 24-h treatment and the
sigma-2 moiety in SW III-123 delivers the SMC moiety into
SKOV-3 cells effectively.
Viability assays were also performed in two other human
ovarian cancer cell lines, CaOV-3 and BG-1 (Figures 2B and C, and
Supplementary Figure 1). The EC50 values for these compounds in
three human ovarian cell lines are shown in Table 1. The results
showed that SW IV-52s had no cytotoxicity in these two cell lines,
whereas SW III-123 showed potent cytotoxicity, suggesting
that sigma-2 moiety of SW III-123 delivers the SMC moiety into
SMC-insensitive cell lines.
In order to study if the entry of SW III-123 into SKOV-3 cells is
mediated by sigma-2 receptors, we examined whether SW III-123
can block internalisation of SW 120, a fluorescent sigma-2 probe,
into cells. SKOV-3 cells were pre-treated with SW 43, SW IV-52s
or SW III-123 for 30min, and then incubated with SW 120 for
another 30min. Internalisation of SW 120 was analysed by flow
cytometer. The results showed that SW 43 and SW III-123 blocked
the internalisation of SW 120 by 40% and 57%, respectively,
whereas SW IV-52s did not block the internalisation (Figure 2D).
The data suggest that the sigma-2 ligand delivers SMC into the
cells, in fairly large part, through sigma-2 receptor-mediated
mechanism.
SW IV-52s and SW III-123, but not SW 43, rapidly degraded
cIAP1 and cIAP2. In order to study the mechanisms of cell killing
by SW III-123, we studied effects of this compound on protein
levels of IAPs. SKOV-3 cells were treated with 0, 1, 3 and 10 mM of
SW 43, SW IV-52s or SW III-123 for 24 h. Western blot data
showed that SW IV-52s and SW III-123 markedly decreased
cIAP1 and cIAP2 protein levels in a dose-dependent manner
(Figure 3A). SW IV-52s and SW III-123 slightly decreased XIAP
expression as the drug concentration increased. SW 43 did not
have any effect on cIAP1, cIAP2 or XIAP protein levels. We also
treated SKOV-3 cells with 3mM of SW 43, SW IV-52s or SW III-
123 for 0, 0.5, 2, 6 and 24 h. The western blot results showed that
SW IV-52s and SW III-123, but not SW 43, induced rapid




































































































Figure 2. SW III-123 potently induced cell death in ovarian cancer cells. SKOV-3 (A), CaOV-3 (B) or BG-1 (C) cells were treated with increasing
concentrations of SW 43 (J), SW IV-52s (K), the combination of SW 43 and SW IV-52s (&), or SW III-123 (’) for 24 h. Cell viability was
determined by MTS assay. (D) Flow cytometric determination of the internalisation of SW120 in SKOV-3 cells with the blocking compound
of SW 43 (’), SW IV-52s (m) or SW III-123 (K). The bars represent mean±s.e.m. in at least three independent experiments.
Table 1. Cytotoxicity of SW 43, SW IV-52s and SW III-123 in human ovarian cancer cells
SKOV-3 SKOV-3 CaOV-3 CaOV-3 BG-1 BG-1
Compound EC50±s.e. (mM, 24 h) EC50±s.e. (mM, 48 h) EC50±s.e. (mM, 24 h) EC50±s.e. (mM, 48 h) EC50±s.e. (mM, 24 h) EC50±s.e. (mM, 48 h)
SW 43 25.2±0.7 19.7±0.8 15.9±1.1 14.0±0.5 24.0±0.9 24.1±2.1
SW IV-52s 4100 0.7±0.1 4100 4100 4100 4100
SW III-123 4.0±0.6 1.4±0.3 2.8±0.1 1.3±0.1 2.3±0.1 1.3±0.1
BRITISH JOURNAL OF CANCER Sigma-2 ligands as tumour-targeted drug delivery agents
2372 www.bjcancer.com |DOI:10.1038/bjc.2013.593
the earliest time point tested after drug treatment. In contrast, none
of the three compounds significantly affected XIAP protein levels
at any time point. The data suggest that the sigma-2 ligand moiety
of SW III-123 does not have a role either in cIAP1/2 degradation
or its downstream signalling, and it functions as a drug delivery
agent. The SW IV-52s moiety of SW III-123 is responsible for
cIAP1/2 degradation and subsequent cell killing mechanisms.
SW IV-52s and SW III-123, but not SW 43, cleaved pro-caspase-8,
-9 and -3. XIAP has been shown to be a potent inhibitor of
caspase-9 and caspase-3. Both cIAP1 and cIAP2 are implicated in
suppression of caspase-8 activation during TNFa signalling
(Deveraux et al, 1998; Wang et al, 1998). Therefore, we studied
if SW IV-52s or SW III-123 induced caspase-8, -9 and -3
activation by western blot analysis. The data showed that SW IV-52s
and SW III-123, but not SW43, triggered pro-caspase-8, -9 and -3
cleavage in a dose-dependent manner after 24-h treatment
(Figure 3A). In all, 3mM of SW IV-52s or SW III-123, but not
SW 43, induced pro-caspase-8, -9 and -3 cleavage in a time-
dependent manner (Figure 3B). These data suggest that SW IV-52s
and SW III-123 activated both intrinsic and extrinsic apoptotic
pathways.
SW IV-52s and SW III-123, but not SW 43, induced NF-kB
activation and TNFa-dependent apoptosis. cIAP1 and cIAP2
were originally identified by their association with TNFR2 via
TRAF1 and TRAF2 (Rothe et al, 1995; Uren et al, 1996). It has
been suggested that degradation of cIAP1 and cIAP2 by SMC
activates NF-kB pathway and induces production of TNFa, a target
of NF-kB transcription factors. Therefore, we examined if
SW IV-52s or SW III-123 induced NF-kB activation in SKOV-3
cells. Western blot results showed that SW IV-52s and SW III-123,
but not SW 43, induced phosphorylation of NF-kB p65 in a dose-
dependent manner after 24-h treatment (Figure 4A). In all, 3 mM of
SW IV-52s or SW III-123 induced phosphorylation of NF-kB p65
in a time-dependent manner (Figure 4B). Phosphorylation of
NF-kB p65 occurred as early as 5min after treatment with
SW III-123 (Supplementary Figure 2). These data suggest that
canonical NF-kB signalling pathway is activated. The data also
showed that SW IV-52s and SW III-123, but not SW 43, induced
NF-kB-inducing kinase (NIK) accumulation in a dose-dependent
manner after 24-h treatment. In total, 3mM of SW IV-52s or
SW III-123 significantly increased NIK protein level (Figure 4B) in
a time-dependent manner. The results suggest that noncanonical
NF-kB signalling pathway is activated.
In order to examine if the cell death induced by SW IV-52s or
SW III-123 is TNFa dependent, we measured caspase-3 activity in
a cell-based assay in the presence or absence of TNFa antibody.
SKOV-3 cells were pre-treated with or without 2 mgml–1 TNFa
antibody for 1 h, and then treated with 3 mM SW IV-52s, SW 43 or
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Figure 3. SW IV-52s and SW III-123 rapidly degraded cIAP1 and cIAP2
and cleaved pro-caspase-8, -9, and -3. (A) SKOV-3 cells were treated
with 0, 1, 3 and 10mM SW 43, SW IV-52s or SW III-123 for 24 h. The
whole-cell lysates were analysed by western blot. (B) SKOV-3 cells were
treated with 3 mM of SW 43, SW IV-52s or SW III-123 for indicated time.
The whole-cell lysates were analysed by western blot.
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Figure 4. SW IV-52s and SW III-123 induced NF-kB activation.
(A) SKOV-3 cells were treated with 0, 1, 3 and 10mM SW 43, SW IV-52s
or SW III-123 for 24 h. The whole-cell lysates were analysed by western
blot. (B) SKOV-3 cells were treated with 3 mM of SW 43, SW IV-52s or
SW III-123 for indicated time. The whole-cell lysates were analysed by
western blot.
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SW III-123 for 24h. The cells were assayed for caspase-3 activity.
The data showed that SW IV-52s and SW III-123, but not SW 43,
induced caspase-3 activity, and TNFa antibody markedly blocked
caspase-3 activation induced by either compound (Figure 5A). We
also performed MTS viability assay in the presence or absence of
TNFa antibody. We showed that TNFa antibody significantly
blocked cell death induced by 3 or 10 mM SW IV-52s (Figure 5C) or
by 3mM SW III-123 (Figure 5D). These data suggest that SW IV-
52s and SW III-123 induced TNFa-dependent apoptosis in
SKOV-3 cells.
TNFa antibody blocking experiments were also performed in
SMC-insensitive ovarian cell lines, CaOV-3 and BG-1. We have
shown that SW III-123 induced caspase-3 activation and cell death
in these two cell lines. However, unlike in SKOV-3 cells, TNFa
antibody did not block SW III-123 induced caspase-3 activation
and cell death in CaOV-3 and BG-1 cells (Supplementary Figures 3
and 4), suggesting that SW III-123 induced TNFa-independent
cell death in SMC-insensitive cell lines.
DISCUSSION
A major limitation of conventional chemotherapy is toxicity of
anticancer drugs to normal tissues. Development of tumour-
targeted drug delivery agent represents an important strategy to
overcome this problem. By using PET imaging technology, our
laboratory has shown that 18F-labelled sigma-2 ligand specifically
bind to tumours in mouse models (Tu et al, 2007) and in human
clinical studies (Dehdashti et al, 2013). In addition, we have
demonstrated that fluorescent sigma-2 ligands are rapidly inter-
nalised into cancer cells by endocytosis (Zeng et al, 2007, 2011).
These findings led us to propose that sigma-2 ligands can be used
as a tumour-targeting drug delivery agent.
In this study, we evaluated this strategy by synthesising a sigma-
2 ligand-conjugated drug and studying its cell killing mechanisms.
We have attached a sigma-2 ligand, SW 43, to an anticancer drug,
SW IV-52s to form SW III-123. It was reported that SW IV-52s
binds to BIR3 domain of XIAP with high affinity (Kd¼ 12 nM) and
is effective in rescuing XIAP BIR3-mediated inhibition of caspase
activity in a cell-free functional assay (Oost et al, 2004; Sun et al,
2008). We showed that SW IV-52s treatment for 24 h induced
minor cytotoxicity (EC50,24h 4100 mM) in SKOV-3 cells, whereas
SW III-123-induced cell death potently (EC50,24h¼ 4.0 mM). We
also showed that SW IV-52s did not exhibit cytotoxicity in CaOV-
3 and BG-1 cells, whereas SW III-123 strongly induced cell death
in both cell lines (Table 1, Figure 2 and Supplementary Figure 1).
The strong cell killing potency of SW III-123 is not due to the
additive or synergistic effects of SW 43 and SW IV-52s, because
the combination of these two compounds induced much less
cytotoxicity than the covalently conjugated compound, SW III-123
(Figure 2A). The data suggest that the sigma-2 ligand (SW 43)
moiety of SW III-123 delivers the SMC moiety into cancer cells.
Multiple mechanisms may be responsible for the potent cytotoxi-
city of SW III-123. (1) Compared with SW IV-52s, the
intracellular concentration of the SMC moiety of SW III-123
could be increased because of sigma-2 receptor-mediated delivery
mechanisms. (2) The subcellular localisation of the SMC moiety of
SW III-123 could be different from that of SW IV-52s. Previously,
we have shown that a sigma-2 fluorescent probe, SW120, which is
an analogue of SW 43, is internalised into cells through
endocytotic mechanisms and distributed in mitochondria, endo-
plasm reticulum and lysosome (Zeng et al, 2011). It is possible that
the SW 43 moiety directs the SMC moiety into the SW 43-targeted
subcellular organelles where the SMC moiety could interact with
IAPs and induce cell death. (3) The SMC moiety of SW III-123
could potentiate the cytotoxicity of the SW 43 moiety. Figure 2
showed that SW 43 was cytotoxic although at concentrations much
higher than SW III-123. The mechanisms of SW 43-elicited
cytotoxicity was reported recently. SW 43 induced lysosomal
membrane permeabilisation, cathepsin B leakage from lysosome,
cellular oxidative stress and caspase-3-independent apoptosis
(Hornick et al, 2012). The cytotoxic effects of the SMC moiety
could make cells more susceptible to the cytotoxicity of the SW 43
moiety. These possible mechanisms deserve further study.
Previous studies demonstrated that SMCs display cell killing
effects only in a subset of cell lines (Sun et al, 2008). Our data
showed that SW IV-52s exhibited cytotoxicity in SKOV-3 cells, but
not in CaOV-3 or BG-1 cells (Figure 2 and Supplementary
Figure 1). However, SW III-123 showed potent cytotoxicity in all
of the three cell lines. These data suggest that the sigma-2 ligand
can deliver SMC into both SMC-sensitive and SMC-insensitive cell
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Figure 5. SW IV-52s and SW III-123 induced TNFa-dependent
apoptosis. (A) SKOV-3 cells were pre-treated with or without 2mgml–1
TNFa antibody for 1 h, and then treated with 3 mM SW IV-52s, SW 43 or
SW III-123 for 24 h. The cells were assayed for caspase 3 activity. (B–D)
SKOV-3 cells were pre-treated with or without 2 mgml–1 TNFa antibody
for 1 h, and then treated with 3 or 10mM SW 43 (B), SW IV-52s (C) or
SW III-123 (D) for 48 h. Viability of cells was determined by MTS assay.
The representative data from three independent experiments are
shown. *Po0.05.
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lines, expanding the application of SMCs as antitumour agents in
more tumour types. We showed that SW III-123 had adequate
sigma-2 receptor-binding affinity (Ki,s2¼ 189.90 nM), and
significantly blocked internalisation of a fluorescent sigma-2
ligand, SW 120, in SKOV3 cells (Figure 2D), indicating that the
delivery of SMC into tumour cells by the sigma-2 ligand is
mediated by sigma-2 receptors. Collectively, these results provided
the proof-of-concept for sigma-2 receptor-targeted drug delivery.
In order to study the cell death mechanisms induced by SW III-
123 and SW IV-52s, we first examined if these compounds affect
IAP protein levels. We showed that both compounds induced
decreases in cIAP1 and cIAP2 protein levels as early as 0.5 h at
3mM, but had little effect on XIAP protein level within 24-h
treatment (Figures 3A and B). It is reported that cIAP1 and cIAP2
are ubiquitin E3 ligases, and SMC triggers auto-ubiquitination and
subsequent proteasomal degradation of cIAP1 and cIAP2
(Varfolomeev et al, 2007). Thus, it is possible that SW III-123
and SW IV-52s bind to BIR3 of cIAP1 and cIAP2, and change
their conformation, which allows the ubiquitination and subse-
quent proteasomal degradation. We then studied if SW III-123
and SW IV-52s triggers apoptosis. Western blot results showed
that pro-caspase-8, -9 and -3 were cleaved (Figures 3A and B) by
the treatment of these compounds, suggesting that both extrinsic
and intrinsic apoptotic pathways were activated.
Several studies have demonstrated that SMC induces NF-kB
activation and TNFa-dependent cell death (Petersen et al, 2007;
Varfolomeev et al, 2007; Vince et al, 2007). NF-kB family
transcription factors regulate the transcription of a vast array of
proteins in cell survival, proliferation and inflammatory response
(Hayden and Ghosh, 2008; Sun, 2012). The NF-kB signalling
pathways can be classified into canonical and noncanonical
pathways. In the canonical NF-kB pathway, NF-kB family
members form heterodimers, such as p50/p65 dimer. In unstimu-
lated cells, p50/p65 dimers are sequestered in the cytoplasm by
interaction with inhibitors of NF-kB (IkB). In the presence of
stimuli, IkB kinase (IKK) phosphorylates IkBa, triggering its
degradation; this leads to the translocation of p50/p65 dimers into
the nucleus to regulate transcription. In the noncanonical NF-kB
pathway (Sun, 2012), in the absence of noncanonical NF-kB
inducers, newly synthesised NIK is rapidly bound by TRAF3 and
targeted to TRAF-cIAP ubiquitin ligase complex, where cIAP1 and
cIAP2 catalyse ubiquitination of NIK through their ubiquitin E 3
ligase activity, targeting NIK for degradation in the proteasome. In
cells stimulated by noncanonical signals, NIK is accumulated and
activated. NIK activates IKKa, leading to p100 processing to p52
subunit and nuclear translocation of NF-kB heterodimer p52/RelB
to regulate transcription. In this study, we showed that SW III-123
and SW IV-52s rapidly induced NIK accumulation (Figure 4B),
and NIK accumulation peaked after cIAP1 and cIAP2 degradation
(Figures 3B and 4B). It is likely that degradation of cIAP1 and
cIAP2 upon the treatment of SW III-123 and SW IV-52s prevents
ubiquitination of NIK by cIAP1 and cIAP2 and its proteasomal
degradation, leading to NIK stabilisation and activation of the
noncanonical NF-kB signalling pathway. In addition, we showed
that SW III-123 and SW IV-52s induced phosphorylation of NF-
kB p65 as early as 5min after the treatment (Figures 4A and B, and
Supplementary Figure 2). It is reported that phosphorylation of
NF-kB p65 is required for an optimal activation of canonical NF-
kB signalling (Viatour et al, 2005). Thus, our data suggest that
canonical NF-kB pathway is activated as well. As shown in Figures
4A and B, SW IV-52s induced more NIK accumulation than SW
III-123. SW IV-52s is an optically active compound, containing an
(S)-alanyl group, whereas SW III-123 is a racemic compound
(i.e., R/S-alanyl group). It is possible that only one enantiomer of
SW III-123 is biologically active and the racemic SW III-123 is not
as effective as SW IV-52s in inducing NIK accumulation. The
positive results described in this study led to our devising a new
synthetic route for preparing optically pure SW III-123. Future
studies with this compound will utilise the optically pure
compound.
TNFa is one of the target genes for NF-kB transcription factors.
We determined if the cell death induced by SW III-123 and SW
IV-52s is TNFa dependent. We showed that TNFa antibody
markedly inhibited caspase-3 activation and cell death induced by
both compounds (Figures 5A–D) in SKOV-3 cells. These data
indicated that NF-kB-induced TNFa is a key player in SW III-123
and SW IV-52s-triggered cell death. The binding of TNFa to
TNFR1 has been shown to initiate the extrinsic apoptotic pathway
(Aggarwal, 2003). The binding of TNFa to TNFR1 recruits Fas-
associated death domain protein, Fas-associated death domain
protein and caspase-8. Upon recruitment, caspase-8 is activated by
self-cleavage, and then activates caspase-3. It is possible that SW
III-123 and SW IV-52s triggered caspase-8 and -3 cleavage
(Figure 3) through sequential events of activation of NF-kB, TNFa
production and TNFa-induced extrinsic apoptotic pathway.
Our data showed that TNFa antibody did not block SW III-123
induced caspase-3 activation and cytotoxicity in SMC-insensitive
ovarian cell lines, CaOV-3 and BG-1 (Supplementary Figure 3 and 4),
suggesting that SW III-123 induced TNFa-independent cell
death. The data are consistent with the previous report that SMC
does not induce TNFa production in SMC-insensitive cell lines
(Vince et al, 2007). It is not clear why some cells are SMC-sensitive
and some are not. The molecular mechanisms of SW III-123-
induced cell death in SMC-insensitive cells deserve further studies.
Sigma-2 ligand-conjugated SMC may offer a new class of drugs for
treating SMC-insensitive cancer cells. We showed that SW III-123
and SW IV-52s induced caspase-9 cleavage, suggesting that
intrinsic apoptotic pathway is activated. One possible mechanism
for caspase-9 activation is that the activated caspase-8 via extrinsic
pathway engages the intrinsic pathway by cleaving the proapopto-
tic BCL-2 family member BID (BH3 interacting-domain death
agonist). It is reported that during extrinsic apoptosis caspase-8 is
enriched on the mitochondrial surface and form native complex
with BID in some cell types (Schug et al, 2011). Following extrinsic
apoptotic stimuli, active caspase-8 cleaves BID. The cleaved BID
interacts with other BCL-2 family members on the surface of the
mitochondria, which results in mitochondrial outer membrane
permeabilisation, cytochome c release, apoptosome assembly,
caspase-9 cleavage and subsequent caspase-3 activation. XIAP
binds and inhibits caspase-9 through its BIR3 domain (Shiozaki
and Shi, 2004), whereas SMCs such as SW III-123 or SW IV-52s
have been shown to bind XIAP BIR3 and remove the inhibition of
XIAP for caspase-9, thereby promoting apoptosis.
On the basis of our data and the findings in the literature, we
propose a model for SW III-123-induced cell death signalling
pathways in SMC-sensitive cell lines (Figure 6). SW III-123 is
internalised into cells via sigma-2 receptor-mediated endocytosis.
Upon entering cells, SW III-123 binds to cIAP1 and cIAP2 in their
BIR3 domain and induces rapid degradation of cIAP1 and
cIAP2 and accumulation of NIK, which initiates noncanonical
NF-kB pathway. Canonical NF-kB signalling is also activated as
SW III-123 induced phosphorylation of NF-kB p65 (Figure 4).
The activation of NF-kB transcription factor induces expression of
TNFa, which then binds to TNFRs and triggers the extrinsic
apoptotic pathway, resulting in caspase-8 activation and subse-
quent caspase-3 activation. Active caspase-8 in turn triggers the
intrinsic apoptotic pathway presumably via cleaving BID on the
surface of mitochondria, leading to caspase-9 and -3 activation.
SW III-123 binds to XIAP BIR3, which disrupts interaction of
XIAP and caspase-9, and thus activates caspase-9 and caspase-3. In
summary, SW III-123 delivers SMC into ovarian cancer cells and
then binds to IAPs and induces TNFa-dependent apoptosis.
Conjugating a sigma-2 ligand to an anticancer drug provides a
platform for delivering drugs selectively into tumour cells. The
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sigma-2 receptor ligand may be exploited to carry any cytotoxic
drug or drug-loaded nanoparticles to various tumours that
overexpress the sigma-2 receptor. Sigma-2 receptor ligand-linked
therapeutic agents will likely display reduced off-site toxicity and
enhanced potency against tumour cells. These features could lead
to improved treatment regimens and cancer patient outcomes.
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Figure 6. A model for cell death signalling pathways induced by
SW III-123. SW III-123 is internalised cells through sigma-2 receptor
(s2R)-mediated endocytosis. SW III-123 degrades cIAP1 and cIAP2,
and thus antagonises cIAP1/2-mediated NF-kB-inducing kinase (NIK)
degradation, induces nuclear factor (NF)-kB activation and subsequent
tumour necrosis factor alpha (TNFa) production. TNFa binds to TNFR
and induces extrinsic and intrinsic apoptotic pathways, leading to
caspase-8, -9 and -3 activation. SW III-123 also binds to XIAP, and thus
removes the inhibition of XIAP to caspase-9, promoting apoptosis. IAP,
inhibitor of apoptosis protein.
BRITISH JOURNAL OF CANCER Sigma-2 ligands as tumour-targeted drug delivery agents
2376 www.bjcancer.com |DOI:10.1038/bjc.2013.593
Vangveravong S, Xu J, Zeng C, Mach RH (2006) Synthesis of N-substituted
9-azabicyclo[3.3.1]nonan-3alpha-yl carbamate analogs as sigma2 receptor
ligands. Bioorg Med Chem 14: 6988–6997.
Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N,
Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, Flygare JA,
Fairbrother WJ, Deshayes K, Dixit VM, Vucic D (2007) IAP antagonists
induce autoubiquitination of c-IAPs, NF-kappaB activation, and
TNFalpha-dependent apoptosis. Cell 131: 669–681.
Viatour P, Merville MP, Bours V, Chariot A (2005) Phosphorylation of
NF-kappaB and IkappaB proteins: implications in cancer and inflammation.
Trends Biochem Sci 30: 43–52.
Vilner BJ, Bowen WD (1993) Sigma receptor-active neuroleptics are cytotoxic
to C6 glioma cells in culture. Eur J Pharmacol 244: 199–201.
Vilner BJ, de Costa BR, Bowen WD (1995) Cytotoxic effects of sigma ligands:
sigma receptor-mediated alterations in cellular morphology and viability.
J Neurosci 15: 117–134.
Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA,
Chunduru SK, Condon SM, McKinlay M, Brink R, Leverkus M,
Tergaonkar V, Schneider P, Callus BA, Koentgen F, Vaux DL, Silke J
(2007) IAP antagonists target cIAP1 to induce TNFalpha-dependent
apoptosis. Cell 131: 682–693.
Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr. AS (1998)
NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1
and c-IAP2 to suppress caspase-8 activation. Science 281: 1680–1683.
Wang S (2011) Design of small-molecule Smac mimetics as IAP antagonists.
Curr Top Microbiol Immunol 348: 89–113.
Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, Keng PC,
Mach RH (2000) Sigma-2 receptors as a biomarker of proliferation in solid
tumours. Br J Cancer 82: 1223–1232.
Xu J, Tu Z, Jones LA, Vangveravong S, Wheeler KT, Mach RH (2005)
[3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-
methoxy-5 -methylbenzamide: a novel sigma-2 receptor probe. Eur J
Pharmacol 525: 8–17.
Xu J, Zeng C, Chu W, Pan F, Rothfuss JM, Zhang F, Tu Z, Zhou D, Zeng D,
Vangveravong S, Johnston F, Spitzer D, Chang KC, Hotchkiss RS,
Hawkins WG, Wheeler KT, Mach RH (2011) Identification of the
PGRMC1 protein complex as the putative sigma-2 receptor binding site.
Nat Commun 2: 380.
Yang C, Davis JL, Zeng R, Vora P, Su X, Collins LI, Vangveravong S,
Mach RH, Piwnica-Worms D, Weilbaecher KN, Faccio R, Novack DV
(2013) Antagonism of inhibitor of apoptosis proteins increases bone
metastasis via unexpected osteoclast activation. Cancer Discov 3:
212–223.
Zeng C, Vangveravong S, Jones LA, Hyrc K, Chang KC, Xu J, Rothfuss JM,
Goldberg MP, Hotchkiss RS, Mach RH (2011) Characterization and
evaluation of two novel fluorescent sigma-2 receptor ligands as
proliferation probes. Mol Imaging 10: 420–433.
Zeng C, Vangveravong S, Xu J, Chang KC, Hotchkiss RS, Wheeler KT, Shen D,
Zhuang ZP, Kung HF, Mach RH (2007) Subcellular localization of sigma-2
receptors in breast cancer cells using two-photon and confocal microscopy.
Cancer Res 67: 6708–6716.
This work is published under the standard license to publish agree-
ment. After 12 months the work will become freely available and
the license terms will switch to a Creative Commons Attribution-
NonCommercial-Share Alike 3.0 Unported License.
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
Sigma-2 ligands as tumour-targeted drug delivery agents BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2013.593 2377
